These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 30204722)
1. Advancing HIV Biomedical Prevention Research for At-Risk Adolescents. Kapogiannis BG; Nelson RM; Siberry GK; Lee S; Hazra R J Acquir Immune Defic Syndr; 2018 Dec; 79(5):535-542. PubMed ID: 30204722 [TBL] [Abstract][Full Text] [Related]
2. HIV Preexposure Prophylaxis Among Adolescents in the US: A Review. Yusuf H; Fields E; Arrington-Sanders R; Griffith D; Agwu AL JAMA Pediatr; 2020 Nov; 174(11):1102-1108. PubMed ID: 32391878 [TBL] [Abstract][Full Text] [Related]
3. Preventing HIV among adolescents with oral PrEP: observations and challenges in the United States and South Africa. Hosek S; Celum C; Wilson CM; Kapogiannis B; Delany-Moretlwe S; Bekker LG J Int AIDS Soc; 2016; 19(7(Suppl 6)):21107. PubMed ID: 27760684 [TBL] [Abstract][Full Text] [Related]
4. Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth. Mullins TL; Zimet G; Lally M; Kahn JA AIDS Patient Care STDS; 2016 Jul; 30(7):339-48. PubMed ID: 27410497 [TBL] [Abstract][Full Text] [Related]
5. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE. Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I; BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719 [TBL] [Abstract][Full Text] [Related]
6. Getting youth PrEPared: adolescent consent laws and implications for the availability of PrEP among youth in countries outside of the United States. Taggart T; Bond KT; Ritchwood TD; Smith JC J Int AIDS Soc; 2019 Jul; 22(7):e25363. PubMed ID: 31369211 [TBL] [Abstract][Full Text] [Related]
7. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes. Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199 [TBL] [Abstract][Full Text] [Related]
8. HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. Mullins TLK; Zimet G; Lally M; Xu J; Thornton S; Kahn JA AIDS Patient Care STDS; 2017 Dec; 31(12):504-516. PubMed ID: 29211514 [TBL] [Abstract][Full Text] [Related]
9. Adolescent Health Providers' Willingness to Prescribe Pre-Exposure Prophylaxis (PrEP) to Youth at Risk of HIV Infection in the United States. Hart-Cooper GD; Allen I; Irwin CE; Scott H J Adolesc Health; 2018 Aug; 63(2):242-244. PubMed ID: 29843969 [TBL] [Abstract][Full Text] [Related]
10. Promise and pitfalls of pre-exposure prophylaxis for female sex workers. Cowan FM; Delany-Moretlwe S Curr Opin HIV AIDS; 2016 Jan; 11(1):27-34. PubMed ID: 26633639 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L; Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274 [TBL] [Abstract][Full Text] [Related]
12. Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice. Haberer JE Curr Opin HIV AIDS; 2016 Jan; 11(1):10-7. PubMed ID: 26633638 [TBL] [Abstract][Full Text] [Related]
13. Minors' and Young Adults' Experiences of the Research Consent Process in a Phase II Safety Study of Pre-exposure Prophylaxis for HIV. Knopf AS; Ott MA; Liu N; Kapogiannis BG; Zimet GD; Fortenberry JD; Hosek SG J Adolesc Health; 2017 Dec; 61(6):747-754. PubMed ID: 28967541 [TBL] [Abstract][Full Text] [Related]
14. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pre-exposure prophylaxis for HIV: a review. Schackman BR; Eggman AA Curr Opin HIV AIDS; 2012 Nov; 7(6):587-92. PubMed ID: 23076124 [TBL] [Abstract][Full Text] [Related]
16. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
17. Statistical issues in trials of preexposure prophylaxis. Dunn DT; Glidden DV Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264 [TBL] [Abstract][Full Text] [Related]
18. Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States. Aaron E; Blum C; Seidman D; Hoyt MJ; Simone J; Sullivan M; Smith DK AIDS Patient Care STDS; 2018 Jan; 32(1):16-23. PubMed ID: 29323558 [TBL] [Abstract][Full Text] [Related]
19. Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns. Tetteh RA; Yankey BA; Nartey ET; Lartey M; Leufkens HG; Dodoo AN Drug Saf; 2017 Apr; 40(4):273-283. PubMed ID: 28130774 [TBL] [Abstract][Full Text] [Related]
20. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Siegler AJ; Mouhanna F; Giler RM; Weiss K; Pembleton E; Guest J; Jones J; Castel A; Yeung H; Kramer M; McCallister S; Sullivan PS Ann Epidemiol; 2018 Dec; 28(12):841-849. PubMed ID: 29983236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]